ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population

[11] Asumi M(2015)Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update AAPS J 17 65-289

[12] Sugawara A(2009)Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population Sci Transl Med 1 5ra11-242

[13] Totsuka K(2014)ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload Sci Rep 4 3755-1446

[14] Saito A(2016)ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout The Pharmacogenomics Journal 17 201-5228

[15] Sone H(2015)2015 gout classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative Arthritis Rheumatol 67 2557-225

[16] Zhu Y(2016)Predicting allopurinol response in patients with gout Br J Clin Pharmacol 81 277-3464

[17] Pandya BJ(2016)Allopurinol hypersensitivity: investigating the cause and minimizing the risk Nat Rev Rheumatol 12 235-154

[18] Choi HK(2010)The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial Arthritis Res Ther 12 R63-909

[19] Kanji T(2012)2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Arthritis Care Res 64 1431-26838

[20] Gandhi M(2013)Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules Proc Natl Acad Sci 110 5223-1795

[11] Asumi M(2015)Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update AAPS J 17 65-289

[12] Sugawara A(2009)Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population Sci Transl Med 1 5ra11-242

[13] Totsuka K(2014)ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload Sci Rep 4 3755-1446

[14] Saito A(2016)ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout The Pharmacogenomics Journal 17 201-5228

[15] Sone H(2015)2015 gout classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative Arthritis Rheumatol 67 2557-225

[16] Zhu Y(2016)Predicting allopurinol response in patients with gout Br J Clin Pharmacol 81 277-3464

[17] Pandya BJ(2016)Allopurinol hypersensitivity: investigating the cause and minimizing the risk Nat Rev Rheumatol 12 235-154

[18] Choi HK(2010)The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial Arthritis Res Ther 12 R63-909

[19] Kanji T(2012)2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Arthritis Care Res 64 1431-26838

[20] Gandhi M(2013)Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules Proc Natl Acad Sci 110 5223-1795